LeMaitre Vascular Inc (LMAT)vsMerck & Company Inc (MRK)
LMAT
LeMaitre Vascular Inc
$80.59
+2.27%
HEALTHCARE · Cap: $1.82B
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 25266% more annual revenue ($66.57B vs $262.43M). LMAT leads profitability with a 25.0% profit margin vs 4.8%. LMAT appears more attractively valued with a PEG of 2.11. LMAT earns a higher WallStSmart Score of 62/100 (C+).
LMAT
Buy62
out of 100
Grade: C+
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.5%
Fair Value
$56.44
Current Price
$80.59
$24.15 premium
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 29.0%
Earnings expanding 22.6% YoY
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Smaller company, higher risk/reward
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : LMAT
The strongest argument for LMAT centers on Altman Z-Score, Profit Margin, Operating Margin. Profitability is solid with margins at 25.0% and operating margin at 29.0%.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : LMAT
The primary concerns for LMAT are PEG Ratio, P/E Ratio, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
LMAT profiles as a mature stock while MRK is a value play — different risk/reward profiles.
LMAT carries more volatility with a beta of 0.49 — expect wider price swings.
LMAT is growing revenue faster at 9.6% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
LMAT scores higher overall (62/100 vs 36/100), backed by strong 25.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LeMaitre Vascular Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?